EGFR and non-small cell lung carcinoma: It has been shown that patients with NSCLC who harbor the combination of EGFR L858R/T790M/L718 mutations are resistant to first- and second-generation inhibitors, whereas tumors with L858R/L718, which may occur in the case of first-line osimertinib, seem to be sensitive to afatinib [28,29].